Blueprint Medicines Corporation

109.10-0.0900-0.08%Vol 160.68K1Y Perf 21.47%
Sep 23rd, 2021 14:27 DELAYED
BID109.02 ASK109.10
Open109.16 Previous Close109.19
Pre-Market- After-Market-
 - -%  - -
Target Price
111.00 
Analyst Rating
Strong Buy 1.32
Potential %
1.93 
Finscreener Ranking
★★★★★     59.63
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     62.30
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     80.73
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
64.53 
Earnings Rating
Sell
Market Cap6.39B 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.14
Beta0.71 

Today's Price Range

107.61109.45

52W Range

79.07125.61

5 Year PE Ratio Range

-11.40-16.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
6.05%
1 Month
13.59%
3 Months
30.47%
6 Months
10.45%
1 Year
21.47%
3 Years
56.86%
5 Years
281.78%
10 Years
-

TickerPriceChg.Chg.%
BPMC109.10-0.0900-0.08
AAPL146.760.91000.62
GOOG2 841.3022.53000.80
MSFT299.831.25000.42
XOM57.151.94003.51
WFC47.970.89001.89
JNJ165.371.44000.88
FB346.112.90000.84
GE103.635.09005.17
JPM161.575.66003.63
Financial StrengthValueIndustryS&P 500US Markets
5.30
5.60
0.05
0.06
-63 864.90
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
99.20
40.90
41.70
-393.40
41.31
RevenueValueIndustryS&P 500US Markets
828.10M
14.14
156.30
101.18
Earnings HistoryEstimateReportedSurprise %
Q02 2021-1.77-1.86-5.08
Q01 2021-1.80-1.724.44
Q04 2020-1.57-1.532.55
Q03 20206.4911.1671.96
Q02 2020-2.08-2.28-9.62
Q01 2020-2.15-2.111.86
Q04 2019-1.71-1.3521.05
Q03 2019-2.19-1.9311.87
Earnings Per EndEstimateRevision %Trend
9/2021 QR-1.65-2.48Negative
12/2021 QR-1.55-0.65Negative
12/2021 FY-6.66-2.15Negative
12/2022 FY-5.72-2.51Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-1.65
Estimates Count8
EPS Growth Next 5 Years %34.00
Volume Overview
Volume160.68K
Shares Outstanding58.57M
Shares Float58.21M
Trades Count3.22K
Dollar Volume35.97M
Avg. Volume462.54K
Avg. Weekly Volume395.11K
Avg. Monthly Volume405.25K
Avg. Quarterly Volume451.65K

Blueprint Medicines Corporation (NASDAQ: BPMC) stock closed at 109.19 per share at the end of the most recent trading day (a 1.47% change compared to the prior day closing price) with a volume of 316.32K shares and market capitalization of 6.39B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Blueprint Medicines Corporation CEO is Jeffrey W. Albers.

The one-year performance of Blueprint Medicines Corporation stock is 21.47%, while year-to-date (YTD) performance is -2.64%. BPMC stock has a five-year performance of 281.78%. Its 52-week range is between 79.07 and 125.61, which gives BPMC stock a 52-week price range ratio of 64.53%

Blueprint Medicines Corporation currently has a PE ratio of 17.80, a price-to-book (PB) ratio of 4.67, a price-to-sale (PS) ratio of 7.44, a price to cashflow ratio of 15.20, a PEG ratio of 2.32, a ROA of 27.98%, a ROC of 32.57% and a ROE of 35.03%. The company’s profit margin is 41.31%, its EBITDA margin is 41.70%, and its revenue ttm is $828.09 Million , which makes it $14.14 revenue per share.

Of the last four earnings reports from Blueprint Medicines Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.65 for the next earnings report. Blueprint Medicines Corporation’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Blueprint Medicines Corporation is Strong Buy (1.32), with a target price of $111, which is +1.93% compared to the current price. The earnings rating for Blueprint Medicines Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Blueprint Medicines Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Blueprint Medicines Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.04, ATR14 : 3.07, CCI20 : 163.72, Chaikin Money Flow : 0.22, MACD : 3.95, Money Flow Index : 86.49, ROC : 11.63, RSI : 74.75, STOCH (14,3) : 96.31, STOCH RSI : 1.00, UO : 71.12, Williams %R : -3.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Blueprint Medicines Corporation in the last 12-months were: Anthony L. Boral (Option Excercise at a value of $266 767), Anthony L. Boral (Sold 10 000 shares of value $1 185 200 ), Ariel Hurley (Option Excercise at a value of $49 398), Ariel Hurley (Sold 13 564 shares of value $1 312 313 ), Becker Hewes (Option Excercise at a value of $579 600), Becker Hewes (Sold 13 125 shares of value $1 312 166 ), Charles A. Rowland (Option Excercise at a value of $307 653), Charles A. Rowland (Sold 20 909 shares of value $2 274 309 ), Christina Rossi (Sold 1 704 shares of value $152 313 ), Christopher K. Murray (Sold 1 210 shares of value $104 984 ), Debra Durso-Bumpus (Option Excercise at a value of $68 495), Debra Durso-Bumpus (Sold 3 593 shares of value $317 925 ), George D. Demetri (Sold 758 shares of value $85 010 ), Jeffrey W. Albers (Option Excercise at a value of $935 320), Jeffrey W. Albers (Sold 98 886 shares of value $9 386 857 ), Kathryn Haviland (Option Excercise at a value of $603 585), Kathryn Haviland (Sold 18 695 shares of value $1 856 005 ), Marion Dorsch (Option Excercise at a value of $793 338), Marion Dorsch (Sold 21 378 shares of value $2 170 000 ), Mark A. Goldberg (Option Excercise at a value of $827 229), Mark A. Goldberg (Sold 32 727 shares of value $3 681 795 ), Mark Alan Goldberg (Option Excercise at a value of $827 229), Mark Alan Goldberg (Sold 32 727 shares of value $3 681 795 ), Michael Landsittel (Sold 1 507 shares of value $130 749 ), Nicholas Lydon (Sold 9 815 shares of value $913 595 ), Tracey McCain (Sold 1 893 shares of value $164 242 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (78.57 %)
11 (78.57 %)
8 (66.67 %)
Moderate Buy
1 (7.14 %)
1 (7.14 %)
1 (8.33 %)
Hold
2 (14.29 %)
2 (14.29 %)
3 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.32
Strong Buy
1.32
Strong Buy
1.54

Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

CEO: Jeffrey W. Albers

Telephone: +1 617 374-7580

Address: 45 Sidney Street, Cambridge 02139, MA, US

Number of employees: 429

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

59%41%

Bearish Bullish

55%45%

News

Stocktwits